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ABSTRACT	 	
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Contribution	of	Cortisol	to	Metabolic	Syndrome,	and	it’s	Potential	Implications	in	Depression	
Treatment.	
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The	shared	circuitries	of	depression	and	the	stress	response,	regulated	by	the	
Hypothalamic-Pituitary-Adrenal	(HPA)	axis,	implies	that	major	depression	may	reflect	
dysregulations	of	the	HPA	axis.	Previous	studies	find	that	that	melancholic	depression	is	
accompanied	by	hyperactive	HPA	activity,	anxiety,	insomnia	etc.	Adversely,	patients	with	
atypical	depression	present	CRH	deficiency	accompanied	by	lethargy	and	fatigue.		According	to	
the	corticosteroid	receptor	hypothesis,	HPA	axis	dysregulation	that	causes	these	variable	
phenotypic	depressive	moods	may	be	attributed	to	defective	GR	expression	or	
function.		Multiple	GR	polymorphisms	that	could	impact	its	expression	or	function	have	been	
identified.	Due	to	limitations,	it	was	not	feasible	to	study	a	depressed	patient	population	at	this	
time.	Fortunately,	the	strong	correlation	between	depression	and	obesity	both	being	induced	
HPA	dysregulation	means	that	a	similar	study	can	be	done	by	examining	metabolic	disorders.	
	
A	diagnosis	of	Metabolic	Syndrome	(MS)	requires	patients	to	present	three	or	more	of	
the	following	symptoms:	elevated	fasting	blood	glucose	levels,	elevated	serum	triglyceride	
levels,	low	serum	HDL	levels,	elevated	blood	pressure,	and	truncal	obesity.	This	pathology	
overlaps	with	Cushing’s	Syndrome	(CS)	except	a	diagnosis	of	CS	requires	hypercortisolemia.This	
similarity	has	led	our	lab	and	others	to	hypothesize	that	MS	may	be	a	Cushingoid-like	state	
caused	by	hypersensitivity	of	the	glucocorticoid	receptor	(GR),	a	nuclear	hormone	receptor	that	
is	activated	upon	the	binding	of	cortisol.		Using	an	allele	specific	polymerase	chain	reaction	
(PCR)	protocol,	previous	research	in	our	lab	found	significant	correlations	between	the	BclI	and	
N363S	polymorphisms	of	the	GR	and	altered	patient	metabolic	profiles	in	a	population	of	
patients	seeking	bariatric	surgery.		This	suggests	that	each	contributes	to	obesity	related	
diseases.	Recent	work	in	our	lab	has	expanded	our	study	to	include	the	cortisol	resistance	
polymorphism	TthIII1	(rs10052957)	to	test	the	hypothesis	that	there	would	be	a	decreased	
prevalence	of	this	polymorphism	in	our	subject	population.		The	TthIII1	allele	is	present	at	a	
lower	frequency	in	our	research	population	compared	to	reported	frequencies,	consistent	with	
our	hypothesis.	
	
	 In	addition	to	investigating	the	glucocorticoid	receptor,	we	have	also	developed	an	allele	
specific	PCR	assay	for	previously	identified	single	nucleotide	polymorphisms	(rs12086634	and	
rs846910)	in	the	cortisol	reductase	enzyme	known	as	11beta-hydroxysteroid	dehydrogenase	
(11b-HSD)	type	1.		The	11B-HSD1	enzyme	converts	inactive	cortisone	to	cortisol,	working	
primarily	in	adipose	tissue.		The	polymorphisms	listed	above	are	associated	with	overactivity	of	
the	enzyme	and	may	cause	the	Cushingoid-state	observed	in	MS	patients.	In	our	patient	
population,	the	frequency	of	heterozygosity	for	the	rs12086634	SNP	was	nearly	50%	higher	
than	the	reported	frequency	in	the	general	population,	suggesting	that	this	polymorphism	may	
contribute	to	increased	obesity	and	the	MS	metabolic	profile,	by	increasing	the	localized	
cortisol	in	adipose	tissue.		Greater	understanding	of	the	interplay	between	these	SNPs	can	help	
physicians	and	patients	make	more	informed	decisions	about	treatment	options	for	obesity	and	
metabolic	syndrome.	
	 		
	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Introduction	
Cortisol:	an	overview	
Cortisol	is	a	glucocorticoid,	steroid	hormone	that	has	a	variety	of	physiological	and	
psychological	effects	throughout	the	body.	Therefore,	it	is	no	surprise	that	cortisol	and	similar	
synthetic	analogs	are	commonly	used	to	treat	numerous	diseases,	ranging	from	dermatological	
rashes	to	hematological	malignancies0.	With	its	viable	receptors	expressed	in	nearly	all	
mammalian	cells,	cortisol	influences	many	different	functions1.	The	hormone	contributes	to	the	
regulation	and	function	of	metabolic,	cardiovascular,	immune,	and	physiological	and	
psychological	stress	responses--	all	of	which	are	prone	to	agitation	and	essential	to	restore	
following	the	stimulus	of	an	acute	stressor1,2.			
Of	its	many	target	tissues,	let’s	first	investigate	cortisol’s	role	with	respect	to	peripheral	
tissues.	Cortisol	helps	maintain	energy	homeostasis	by	regulating	metabolism	in	times	of	both	
health	and	disease.	In	the	presence	of	a	physiological	stressor	(famine,	strenuous	exercise	etc.),	
cortisol	acts	on	the	liver	to	increase	gluconeogenesis	and	glycogenolysis,	thereby	restoring	
glucose	levels	through	the	synthesis	of	smaller	derivatives	or	the	breakdown	of	glycogen0.	
Cortisol	impacts	the	catabolism	of	both	lipids	and	proteins.		By	increasing	insulin	resistance,	the	
synthesis	of	very	low-density	lipoproteins,	free	fatty	acid	production,	and	the	circulating	levels	
of	very	low-density	lipoprotein	and	low-density	lipoprotein,	triglyceride	and	cholesterol	levels	
are	increased0.	Insulin	resistance	coupled	with	increased	glucose	levels	induces	greater	insulin	
levels,	leading	to	greater	fat	storage.	Cortisol	influences	the	distribution	and	accumulation	of	
these	increased	fat	levels	in	the	abdominal	region,	often	leading	to	obesity	related	diseases	
when	cortisol	levels	are	high3,4.		
Glucocorticoids	are	released	from	the	adrenal	gland	in	response	to	a	stressor	activating	
the	regulatory	hypothalamic-pituitary-adrenal	(HPA)	axis.	The	role	of	the	HPA	axis	is	to	maintain	
normal	glucocorticoid	secretion.	This	neuroendocrine	system	is	regulated	by	stress	responses,	
glucocorticoid	signaling/feedback	loops,	and	circadian	rhythms2,5.		In	response	to	a	perceived	
stressor,	afferent	neurons	send	a	stimulus	to	the	paraventricular	nucleus	of	hypothalamic	
neurons,	inducing	the	release	of	the	hypothalamic	hormones:	corticotropin-releasing	hormone	
(CRH),	vasopressin,	and	oxytocin2,6.	These	hormones	control	the	release	of	ACTH	from	
corticotroph	cells	in	the	anterior	pituitary6.	Although	vasopressin	and	oxytocin	don’t	induce	
large	secretions	of	ACTH	independently,	when	in	combination,	the	hypothalamic	hormones	
elicit	more	ACTH	than	CRH	could	on	its	
own2.		ACTH	then	binds	to	receptors	
on	the	adrenal	cortex,	where	it	
induces	the	synthesis	and	secretion	of	
glucocorticoids	from	the	zona	
fasciculata6.		
	
Glucocorticoids	are	involved	in	
classic,	multi-variable	endocrine	
feedback	loops	(Figure	1),	which	allow	
for	increased	regulation	of	HPA	stress	
response	and	circulating	glucocorticoid	levels.		CRH	and	ACTH	stimulate	an	increase	in	
glucocorticoid	levels,	while	glucocorticoids	negatively	feedback	on	the	hypothalamus	and	
	
Figure	13.	The	Hypothalamic-Pituitary-Adrenal	(HPA)	axis.	The	numerous	positive	and	negative	feedback	loops	within	this	neuroendocrine	system	are	mapped	out	in	a	simplified	manner.	This	represents	how	stress	initiates	the	pathway	resulting	in	the	production	of	cortisol	and	other	glucocorticoids.	
anterior	pituitary	to	reduce	the	synthesis	and	secretion	of	CRH,	vasopressin,	and	ACTH	
respectively6.	Interestingly,	glucocorticoids	have	no	feedback	inhibition	on	oxytocin2.		The	
circadian	rhythm	is	determined	by	the	activity	of	the	hypothalamic	suprachiasmatic	
nucleus2,5.		Glucocorticoid	secretions	begin	to	spike	just	before	waking,	due	to	the	presence	of	
CRH	and	an	increase	in	the	adrenal	response	to	ACTH2.		This	phenomena,	known	as	the	cortisol	
awakening	response,	leads	to	peak	cortisol	levels	within	a	half	hour	of	waking5.		Cortisol	levels	
then	decrease	relatively	steadily	in	a	diurnal	rhythm,	hitting	a	trough	in	the	late	evening2,5.				
90-95%	of	secreted	glucocorticoids	are	bound	to	corticosteroid-binding	globulin	(CBG),	a	
carrier	protein,	increasing	its	solubility	in	water,	allowing	glucocorticoids	to	travel	effectively	
through	the	circulatory	system1.	When	cortisol	arrives	at	a	target	tissue,	disassociation	with	the	
CBG	occurs,	leaving	behind	a	biologically	available,	lipid	soluble	steroid	that	can	cross	the	cell’s	
bilayer,	bind	to	its	receptor,	enter	the	nucleus,	and	bind	to	its	specific	DNA	region.		Cortisol	
binds	to	both	the	mineralocorticoid	receptor	(MR)	and	the	glucocorticoid	receptor	(GR),	though	
its	affinity	for	the	MR	is	ten	times	stronger	than	its	affinity	for	the	GR7.		The	GR	and	MR	share	
many	similarities	both	in	structure	and	in	expression,	explaining	why	cortisol	acts	as	a	ligand	for	
both	receptors8.		Structurally,	their	DNA	binding	domains	are	94%	homologous9.	While	the	MR	
is	expressed	in	peripheral	tissues,	it	is	highly	expressed	throughout	the	limbic	regions	of	the	
brain,	specifically	in	the	hippocampus,	amygdala	and	prefrontal	cortex2,7.		The	GR	is	expressed	
more	ubiquitously	throughout	the	limbic	system,	especially	in	the	hippocampus,	the	prefrontal	
cortex,	the	paraventricular	nucleus	of	the	hypothalamus,	the	dentate	gyrus,	and	the	amygdala7.	
GRs	are	also	present	in	corticotrophs	and	other	peripheral	tissues7.	
Considering	that	cortisol	has	a	higher	affinity	for	the	MR,	when	at	low	levels,	cortisol	
binds	to	MRs.		Therefore,	MRs	are	responsible	both	for	feedback	inhibition	of	the	HPA	axis	at	
resting	cortisol	levels,	and	for	starting	the	stress	response2,8.	As	cortisol	levels	rise	above	the	
resting	rate,	GR	binding	becomes	more	common8.		The	GR	terminates	the	stress	response	and	
promotes	memory	storage	to	better	prepare	the	body	to	respond	to	that	same	stimulus	in	the	
future8.	At	these	higher	cortisol	levels,	though	the	MR	is	involved,	it	is	the	GR	that	is	the	
primary	contributor	to	HPA	axis	feedback	inhibition8.		In	a	study	from	2011	investigating	the	
relationship	between	glucocorticoids	and	the	immune	system,	Zen	et	al.,	found	that	both	the	
MR	and	the	GR	shared	related	immunosuppressive	functions9.	Though	sample	size	was	cited	as	
a	primary	limitation	in	a	similar	study	performed	by	Cheng	et	al.,	(2016)	they	found	that	during	
low	dose	cortisol	treatments,	the	blocking	effects	on	cortisol-mediated	inflammation	regulation	
were	similar	regardless	of	whether	monocytes’	GRs	or	MRs	were	inhibited8.	
	
	 	
The	Glucocorticoid	Receptor	
The	cortisol-MR	interaction	establishes	an	individual's	basal	response	and	control	of	the	
HPA	axis.	In	addition,	glucocorticoids	have	a	lessened	effect	through	the	MR	because	MRs,	in	
most	tissues	excluding	the	brain,	are	shielded	by	11ß-Hydroxysteroid	dehydrogenase	II	(11ß-
HSDII),	which	converts	the	active	cortisol	into	its	inactive	metabolite,	cortisone0.		Therefore,	
researchers	are	mostly	interested	in	investigating	how	GRs,	which	play	a	larger	role	in	the	stress	
response,	impact	HPA	axis	regulation0-4.			
The	GR	is	a	nuclear	
receptor	encoded	by	NR3C10.	
Located	on	chromosome	5,	it	 has	
nine	exons,	and	follows	a	
normal	nuclear	receptor	
composition:	there	is	an	N-
terminus	transactivation	
domain,	a	C-terminus	ligand	
binding	domain,	with	a	DNA	
binding	domain	in	between7.	
The	9	exons	create	the	opportunity	for	multiple	splice	variants	which,	combined	with	
alternative	translation,	result	in	functional	diversity	within	the	GR7.	GRalpha	is	the	biologically	
active	isoform7.	GRß,	(a	result	of	the	splice	variant	lacking	helix	12)	cannot	bind	glucocorticoids,	
but	can	still	regulate	other	genes7.	GRgamma	is	still	biologically	active,	but	has	significantly	less	
transcriptional	activity	compared	to	GRalpha7.		
	
Figure	20.	Glucocorticoid	Receptor	Isoforms,	formed	by	multiple		promotor	sequences	in	the	9	exons,	alternative	splicing,	different		translational	start	signals,	and	post	translational	modifications.		
The	GC-GR	complex	modulates	target	gene	transcription	through	both	genomic	and	
non-genomic	pathways7.	After	ligand	binding,	the	GR-GC	complex	traffics	towards	the	nucleus	
and	mediates	transcription	in	one	of	many	different	ways.	It	can	promote	GR-GR	dimerization	
on	the	glucocorticoid	response	element	leading	to	chromatin	remodeling,	which	induces	
transactivation7.	If	the	glucocorticoid	binds	to	a	negative	GC	response	element	(located	in	the	
promoter	of	a	target	gene),	gene	transcription	will	be	inhibited.	Glucocorticoids’	nongenomic	
actions	include	influencing	T-cell	receptor	signaling,	increasing	cellular	energy	metabolism,	
modulating	apoptosis,	and	changing	behavior7.	
	
	
HPA	Axis	dysregulation	and	its	implications	on	cortisol,	stress	and	depression	
As	mentioned	previously,	the	numerous	variables	and	regulatory	combinations	in	the	
HPA	axis	and	its	control	system	increase	its	ability	to	maintain	equilibrium	when	activated,	as	
there	are	multiple	checkpoints	where	homeostasis	can	be	restored.	However,	this	also	means	
that	there	are	more	places	for	things	to	go	awry.		Aberrant	HPA	activity,	or	HPA	dysregulation	in	
general,	is	linked	with	various	psychiatric	disorders	as	well	as	obesity8.		HPA	axis	dysregulation	
is	measured	through	a	Dexamethasone	suppression	test	(DST)	or	a	Dexamethasone-CRH	
combined	test	(DEX/CRHT).	In	a	DST,	up	to	2	mg	of	dexamethasone	(an	exogenous	
glucocorticoid)	is	administered	to	measure	the	adrenal	negative	feedback	on	the	pituitary7.	This	
provides	information	on	an	individual’s	baseline	feedback	levels0,2.	DEX/CRHT	is	a	refined	DST	
that	is	a	bit	more	accurate.		In	this	test,	1.5	mg	of	dexamethasone	is	administered	at	around	
11:00	PM,	when	an	individual's	natural	cortisol	levels	should	be	low7.	At	around	3:00	PM	the	
following	day,	100	µg	of	CRH	is	administered7.	Meanwhile,	cortisol	and	ACTH	levels	are	
collected	every	15	minutes	from	2:00	to	6:00	PM7,8.	This	test	provides	information	on	how	
effective	the	positive	and	negative	feedback	loops	of	and	individuals	HPA	axis	are,	and	is	the	
most	sensitive	measure	of	HPA	overactivity	associated	with	depression2.	
The	association	between	HPA	axis	dysregulation	and	depression,	especially	unipolar	and	
bipolar	depressive	disorder,	has	been	established	for	decades7.	Spijker	et	al.,	(2009)	found	that	
80	percent	of	patients	with	a	major	depressive	episode	were	non-suppressors	in	response	to	
the	DEX/CRHT,	further	highlighting	the	linkage	between	HPA	axis	dysregulation	and	
depression7.	This	dysregulation,	leading	to	Major	Depression	Disorder	(MDD)	and	Bipolar	
Depression	(BD)	is	connected	to	anatomical	and	neuroendocrine	alterations	in	brain	function--	
including	changes	in	catecholamines	and	serotonergic	neurotransmission7.		Specifically,	
glucocorticoids	were	found	to	intensify	the	extent	that	dopamine	affects	the	brain's	reward	
system7.	Patients	with	depression	were	also	found	to	have	anatomical	changes	and	altered	
metabolic	activity	in	their	prefrontal	cortex,	amygdala,	and	hippocampus7.	Patients	with	
depression	have	hypometabolism	in	frontal	regions,	and	hypermetabolism	in	the	right	
hippocampus.	Interestingly,	the	metabolic	levels	normalize	with	antidepressant	treatment.				
Stress,	which	activates	the	HPA	axis,	can	be	defined	as	an	actual	(physical)	or	perceived	
(psychological)	threat	to	the	well	being	of	an	organism2.	A	stressed	stimulus	can	be	acute	(brief)	
or	chronic	(long	term).	Physical	and	
mental	health	is	dependent	on	the	
HPA’s	ability	to	regulate	stress.		HPA	
axis	dysregulations	are	associated	
with	different	neuropsychiatric	
diseases.	HPA	overactivity	is	
associated	with	typical	or	melancholic	
depression,	panic	disorder,	OCD	and	
schizophrenia0,1,2,8.		These	are	often	
characterized	by	elevated	24-hour	
free	cortisol,	and	enlarged	adrenal	
glands6.		Low	HPA	axis	activity	is	characteristic	of	atypical	depression8.			
Chronic	stress	induces	GR	dysfunction	or	resistance	(Figure	3),	which	often	leads	to	the	
synthesis	and	secretion	of	more	cortisol	in	an	effort	to	overcome	the	receptor	resistance7.	
However,	the	HPA	response	has	been	shown	to	be	habituated	or	sensitized,	after	repeated	
exposure	to	a	stressful	stimulus11.	The	scientific	community	believes	that	the	observed	inter-
individual	variability	of	HPA	axis	response	to	repeated	stimuli	may	be	caused	by	GR	
variants11.		Depression,	therefore,	may	be	a	result	of	defective	GR	expression	or	function	in	the	
brain	and	corticotroph,	based	on	different	GR	variants	or	isoforms	in	the	tissue	of	interest2.	This	
idea	lead	to	the	formation	of	the	Corticosteroid	receptor	hypothesis,	which	explains	how	
depression	and	the	subsequent	treatment	impact	HPA	activity12.		This	can	be	broken	down	into	
two	parts.	The	first	part	identifies	the	connection	between	depression	and	defective	GR	
Figure	323.	The	Neuropathology	of	stress.	Comparing	the	interactions	between	the	prefrontal	cortex,	the	stress	response,	and	the	immune	system	normally	(left)	vs.	during	chronic	stress	(right).	Note	the	HPA	axis	dysfunction	on	the	left.	
	
expression	or	function,	which	results	in	a	loss	of	inhibitory	feedback,	represented	by	
dexamethasone	resistance,	causing	basal	HPA	activity	to	rise.	This,	in	turn,	results	in	the	
increased	production	of	ACTH-releasing	factors	leading	to	an	increased	ACTH	response	to	
DEX/CRHT13.	Additionally,	post	mortem	evidence	of	individuals	diagnosed	with	MDD	suggests	
they	have	fewer	cerebral	GRs	and	MRs.	The	second	part	identifies	that	proper	treatment	can	
overcome	receptor	deficits2.	
Due	to	the	fact	that	the	GR	isoforms	all	originate	from	the	same	gene,	NR3C1,	GR	
function	is	greatly	impacted	by	mutations	in	that	gene.	Numerous	single-nucleotide	
polymorphisms	(SNPs)	of	the	NR3C1	gene	have	been	identified,	and	are	associated	with	
neuropsychiatric	diseases	as	well	as	altered	lipid	and	carbohydrate	profiles14.	While	many	
studies	have	examined	the	phenotypic	SNPs	with	respect	to	the	corticosteroid	receptor	
hypothesis,	they	all	contain	discrepancies	due	to	differences	in	drug	effects	and	treatment	
times,	indirect	autoregulatory	effects	from	differences	in	glucocorticoid	secretion,	
heterogeneity	of	study	populations,	and	the	fact	that	subtypes	of	depression	have	varying	types	
of	HPA	dysfunction15.			
	 The	
BclI	SNP	
is	caused	
by	a	
C→G		
Figure	415.	Location	of	Single	Nucleotide	Polymorphisms	(SNPs)	of	the	NR3C1.	While	there	are	other	identified	SNPs	of	the	Glucocorticoid	Receptor,	TthIII1,	ER22/23EK,	N363S,	BclI,	and	GR-9ß	are	the	best	studied.		
 	
nucleotide	change	in	intron	2,	646	nucleotides	downstream	of	the	respective	intron	
junction0.		BclI	polymorphisms	are	associated	with	glucocorticoid	hypersensitivity0.	Studies	have	
found	that	unfavorable	metabolic	characteristics	including	insulin	resistance,	diminished	
salivary	cortisol	responses,	and	increased	abdominal	visceral	fat,	body	mass	index	(BMI),	waist	
to	hip	ratio	(WHR),	and	leptin	and	cortisol	responses	to	a	standardized	lunch	are	all	associated	
with	the	G-allele	carriers11.		Three	different	studies	looked	at	the	prevalence	of	homozygous	
mutant	BclI	carriers	in	a	depressed	group	compared	to	a	control	group7.		All	three	studies	found	
that	depressed	group	had	roughly	15.5%	homozygous	mutant,	while	the	control	group	had	
9.9%	express	the	mutant	phenotype	homozygously7.	These	studies	established	a	relationship	
between	the	SNP,	MDD,	and	obesity.	
	 N363S	is	another	GR	hypersensitivity	polymorphism	that	is	the	result	of	an	asparagine	to	
serine	(N→S)	amino	acid	change	in	codon	363	of	exon	2,	which	is	the	result	of	an	AAT→	AGT	
nucleotide	change7.	A	meta-analysis	combining	12	studies	and	containing	5,909	individuals	
aged	25	or	older,	found	that	N363S	carriers	had	increased	BMI	(+0.51	kg/m^2)	compared	to	
non-carriers0.	In	addition	to	increased	BMI,	the	SNP	is	associated	with	higher	WHR,	increased	
cortisol	suppression,	and	increased	salivary	cortisol	in	response	to	an	acute	psychosocial	
stressor11.	Additional	GR	hypersensitivity	SNPs	of	interest	are	RS7701443	and	RS296315624.	 	
	 	 	 	 	
The	ER22/23EK	SNP	is	a	linked	GAG.AGG→GAA.AAG	nucleotide	change	in	codons	22	and	
23	of	the	transactivation	domain7.		The	first	nucleotide	change	is	silent,	as	both	forms	code	for	
glutamic	acid	(E)16.	However,	the	second	nucleotide	change	switches	the	amino	acid	from	
arginine	(R)	to	lysine	(K)16.		This	variant	is	associated	with	GC	resistance,	as	carriers	have	a	
decreased	response	to	DST7,11,15,16.	They	also	had	lower	fasting	insulin	levels,	and	lower	lipid	
profiles	than	noncarriers16.		The	polymorphism	is	associated	with	recurrent	depression	and	
improved	responses	to	antidepressant	medication7.		Multiple	studies	comparing	GR	SNP	
haplotype	frequencies	in	depressed	versus	normal	populations	found	that	the	unipolar	MDD	
group	carrier	frequency	was	8-11%	compared	to	a	healthy	control	group	where	only	4%	carried	
the	polymorphism7.			
	 Another	GR	resistance	polymorphism	is	TthIII1,	which	is	an	SNP	caused	by	a	C→T	change	
6,305	base	pairs	upstream	of	the	first	initiation	codon0.	Initial	findings	suggested	that	TthIII1	
carriers	had	higher	basal	cortisol	levels,	due	to	altered	promoter	activity,	however	this	is	still	
inconclusive,	as	other	research	suggests	that	TthIII1	only	has	effects	when	expressed	in	
combination	with	other	SNPs	including	ER22/23EK	or	BclI0.	
	 Glucocorticoids	have	numerous,	differential	effects	based	on	an	individual's	
glucocorticoid	sensitivity.	This	sensitivity,	and	glucocorticoids	subsequent	action	on	target	
tissues,	is,	in	part,	determined	by	genetics	and	the	functional	NR3C1	polymorphisms	listed	
above.	In	addition,	steroid	access	to	MRs	and	the	enzyme	11ß-HSD	also	play	critical	roles	in	
regulating	glucocorticoid	concentrations.		
The	11ß-HSD	I	and	II	isoforms	regulate	how	much	active	metabolite	is	available	to	bind	
to	receptor24.		Through	 peripheral	
conversion,	11ß-HSDII	 converts	
the	active	metabolite,	 cortisol,	
into	the	inactive	
metabolite,	cortisone,	and	 stores	it	in	
adipose	tissue19.	This	 creates	a	
reservoir	of	potential	cortisol	stored	away	in	fat.	The	type	I	isoform	works	to	access	this	stored	
cortisone	by	converting	it	into	cortisol25,26.	11ß-HSD	is	localized	in	adipose,	liver,	and	lung	
tissue2.	11ß-HSDII	often	guards	MRs,	converting	cortisol	into	its	inactive	metabolite	before	it	
can	act	on	the	receptor2.	This	is	why	GR	polymorphisms	are	more	strongly	associated	with	HPA	
dysregulation,	even	though	glucocorticoids	have	greater	affinity	for	MRs	than	GRs.	Therefore,	
SNPs	leading	to	11ß-HSD	I	overactivity	are	also	of	special	interest	as	they	are	pertinent	to	HPA	
axis	regulation,	and	can	cause	dysregulations	that	promote	neuropsychological	disease,	
metabolic	syndrome,	and	related	comorbidities25,26.	Two	Identified	SNPs	that	induce	11ß-HSD	I	
overactivity	are	RS12086634	and	RS84691025,26.	
	 The	big	picture	is	that	the	GR	plays	a	vital	role	in	mammalian	function.	The	GR	and	its	
associated	polymorphisms	impact	HPA	axis	control	and	cortisol	levels.	A	study	by	Tronche	et	al.,	
(1998)	found	that	GR	knockout	mice	were	unviable,	dying	within	minutes	after	birth	due	to	
collapsed	lungs	as	a	result	of	uncontrolled	inflammation3.			
	
Neuropsychiatric	treatments	and	their	effects	on	HPA	regulation	
 
	
Figure	5.	The	Redox	reaction	conducted	by	the	11ß-HSD	isoforms,	in	order	to	peripherally	convert	cortisone	into	cortisol,	and	vice-versa		
	 Numerous	antidepressants	currently	on	the	market	have	been	associated	with	
decreasing	the	pituitary-adrenal	hyperactivity	common	in	typical	depression.	These	include	
tricyclic	antidepressants,	selective	serotonin	reuptake	inhibitors	(SSRIs),	Bupropion,	
Mirtazapine	(alpha2-adrenergic	antagonist),	and	electroconvulsive	shock	therapy2.	Longitudinal	
studies	where	the	aforementioned	treatments	were	provided	individually	or	in	combination	
showed	increased	ACTH	response	to	the	CRH/DST	as	well	as	the	normalization	of	HPA	hormone	
secretion	to	circadian	patterns	and	a	reduction	in	adrenal	gland	volume	if	enlarged2.	However,	
these	findings	are	not	universal	across	other	similar	studies.		
	 From	these	treatments,	it	is	understood	that	good	treatment	can	overcome	receptor	
deficits,	by	increasing/improving	either	the	function	or	expression	of	the	receptors,	however	
we	do	not	yet	understand	how	antidepressants	mechanistically	normalize	HPA	
activity2.		However,	it	has	recently	been	found	that	antidepressants	affect	GR	expression	
differently	in	different	parts	of	the	brain10.	Atypical	depression,	for	example,	could	be	
successfully	treated	with	either	glucocorticoid	interference	or	glucocorticoid	
supplementation.		Glucocorticoid	interference	would	be	necessary	if	the	GR	is	overactive	or	
over-stimulated	by	high	levels	of	glucocorticoids.	Glucocorticoid	supplementation	would	be	
necessary	if	the	receptor	is	hyposensitive	to	cortisol	or	if	cortisol	levels	are	just	too	
low.		Therefore,	in	order	to	properly	treat	an	individual,	we	need	to	know	their	cortisol	levels	in	
combination	with	their	GR	and	11ß-HSD	haplotype,	meaning	the	SNPs	they	carry.	
Understanding	and	accounting	for	patient	heterogeneity	within	the	context	of	HPA	regulation	is	
the	largest	obstacle	to	overcome	in	order	to	successfully	treat	depression.		
HPA	Axis	Overactivity	and	Obesity	
Factors	in	major	depression	are	directly	linked	to	metabolic	dysfunction,	and	even	
promote	susceptibility	to	heart	disease27.		Since	cortisol	is	essential	to	lipid	and	carbohydrate	
homeostasis,	HPA	overactivity	often	induces	metabolic	dysfunctions			leading	to,	for	example,	
Cushing’s	syndrome	(CS),	which	is	characterized	by	hypercortisolemia18,27.		For	this	reason,	CS	is	
associated	with	MDD,	anxiety	disorder,	other	psychological	diseases,	and	even	reduced	
hippocampal	volume7.		Classically,	CS	patients	present	obesity	related	symptoms	including	
dyslipidemia,	hypertension,	glucose	intolerance,	and	increased	visceral	adiposity1,18,19.	
	
	
The	World	Health	Organization	reports	that	worldwide	obesity	has	more	than	doubled	
since	198020.		With	the	increased	rates	in	obesity	comes	a	rise	in	obesity	related	symptoms	
including	insulin	resistance,	high	triglycerides,	high	blood	pressure,	low	HDL-cholesterol	and	
central	adiposity19.		Having	three	out	of	the	five	stated	symptoms	is	sufficient	in	order	to	
diagnose	Metabolic	Syndrome	(MS)19.		Patients	with	CS	and	MS	share	all	of	the	same	
symptoms,	except	while	CS	is	characterized	by	hypercortisolemia,	MS	is	associated	with	normal	
Figure	727.	Factors	in	major	depression	that	promotes	metabolic	dysregulation	and	related	comorbidities.		
or	even	low	cortisol	levels.	The	lack	in	a	mechanistic	understanding	of	MS	has	lead	to	the	
following	hypothesis:	MS	may	be	a	cushingoid-like	state	with	normal	cortisol	levels,	
accompanied	by	GR	hypersensitivity	and/or	overactive	11ß-HSD	I.	
	 The	increased	rate	of	obesity	is	linked	with	the	popularization	of	bariatric	surgery--	a	
method	to	treat	morbid	obesity.		Currently	there	are	three	main	forms	of	bariatric	surgery:	the	
Roux-en-Y	gastric	bypass,	the	sleeve	gastrectomy	and	the	lap-band.		Studies	show	that	bariatric	
surgery	can	greatly	alter	metabolic	pathways,	inducing	HPA	axis	dysregulation,	which	affects	
weight	loss	and	leads	to	comorbidities	including	hypertension,	hyperlipidemia,	and	depression,	
through	mechanisms	explained	previously22.		Therefore,	the	post-bariatric	population	works	as	
an	experimental	group	representative	of	MS.			
The	purpose	of	this	study	is	to	first	determine	the	prevalence	of	GR	hypersensitivity	
SNPs	(BclI,	N363S,	RS7701443,	RS2963156),	GR	resistance	SNPs	(TthIII1,	ER22/23EK),	and	11ß-
HSD	SNPs	(RS12086634,	RS846910),	in	an	obese,	post-bariatric	population	compared	to	a	
control	or	random	population	composed	of	college	students.		In	addition,	we	want	to	see	how	
the	presence	of	individual	SNPs	and	haplotypes	correlate	with	metabolic	parameters,	including	
BMI,	blood	glucose,	serum	triglycerides,	HDL	and	LDL	cholesterol,	and	systolic	and	diastolic	
blood	pressure	in	the	bariatric	patient	population.	We	also	hope	to	determine	whether	there	is	
a	correlation	between	the	presence	of	certain	SNPs	or	haplotypes	and	the	success	of	specific	
bariatric	surgeries.		We	hope	that	these	findings	can	aid	both	healthcare	providers	and	
potential	bariatric	patients	when	determining	how	to	best	treat	or	manage	their	weight.	
	
	 	
Methods	
	
		
	 	
	
	
	
	
	
DNA	Collection	–	Ellis	Bariatric	Center	
	 DNA	was	collected	from	bariatric	patients	at	Ellis	Bariatric	Center	in	Schenectady,	NY.		
Ellis	Hospital’s	Institutional	Review	Board	approved	the	study	prior	to	collection	beginning	
(Appendix	A).		Prior	to	saliva	collection,	all	potential	participants	were	instructed	on	the	
purpose	of	the	study	and	provided	with	the	option	to	sign	an	informed	consent	form	(Appendix	
B).		If	consent	was	granted,	the	participant	would	pour	~10	mLs	of	a	0.1%	saline	solution	in	their	
mouth,	swish	it	around	for	20-30	seconds,	and	spit	it	out	into	a	collection	cup.	The	wash	
product	was	transferred	into	a	15	mL	centrifuge	tube	and	labeled	with	the	participant’s	medical	
record	number	(MRN).			
	
DNA	Isolation	–	Ellis	Bariatric	Patients	
Chelex	100	beads	by	Bio-Rad©	protocol	was	used	to	isolate	the	DNA	(Appendix	C).	
	
Figure	8.	Summary	of	Research	Approach		
	Isolated	DNA	collection—Union	College	
Union	College’s	Human	Subjects	Review	Committee		approved	this	study	prior	to	DNA	
collection	(Appendix	D).	The	Union	students	who	participated	in	this	study	had	previously	
collected	and	isolated	their	DNA	using	the	same	methods	as	described	above.	After	instructing	
them	on	the	purpose	of	the	study,	Union	students	were	given	an	instruction	sheet	with	a	
random	sample	number	and	a	few	questions	(Appendix	D),	and	an	informed	consent	form	
(Appendix	B).	If	they	consented,	they	filled	out	the	questions	and	transferred	the	contents	of	
their	remaining	isolated	DNA	into	a	1.5	mL	centrifuge	tube,	which	they	then	labeled	with	the	
random	number	on	their	instruction	sheet.	
	
Data	Collection	–	Ellis	Bariatric	Center	
The	relevant	surgery	and	metabolic	parameters	of	participating	patients	was	collected	by	
searching	the	individuals	MRN	in	Ellis	Bariatric	Center’s	electronic	medical	records	(EMR).	Type	
of	surgery,	surgery	date,	pre-surgery	weight	(PSW),	PSW	date,	original	weight,	height,	starting	
BMI,	lowest	weight	(LW),	LW	date,	lowest	BMI,	current	weight	(CW),	CW	date,	current	BMI,	
fasting	blood	glucose,	serum	triglycerides,	Serum	LDL,	Serum	HDL,	systolic	blood	pressure	and	
diastolic	blood	pressure	was	collected.	Using	that	information,	ideal	body	weight,	excess	body	
weight	(EBW),	weight	lost,	and	%EBW	lost,	was	calculated.	
	
	
Allele-specific	PCR	
By	entering	the	known	DNA	sequences	of	desired	SNP’s	into	Web	Based	Allele	Specific	Primer	
(WASP),	wild-type	(WT)	and	mutant	(MT)	primers	were	designed	to	bind	specifically	to	a	target	
polymorphism.	Based	on	annealing	temperatures,	a	desired	primer	set,	consisting	of	common	
primer	that	ran	in	opposition	to	both	the	WT	and	MT	primer,	was	selected	(See	Appendix	E	for	
various	WASP	results	and	selected	primer	information).		
	
PCR	tubes	had	a	total	volume	of	50	µL,	which	was	broken	down	into	the	component	reagents	
according	to	Table	1	below.	
Table	1.	Reagent	Quantities	per	PCR	Tube	
Reagent	 Quantity	
1)	Common	Primer	 1	µL	
2)	WT	or	MT	Primer	 1	µL	
3)	DNA	Template	 8	µL	
4)	dNTPs	 0.5	µL	
5)	Taq	polymerase	 0.5	µL	
6)	Buffer	 5	µL	
7)	DI	Water	 34	µL	
 
 
 
 
 
Table	2.	Tested	Oligonucleotides 
Primer	 Common	 Wild	Type	 Mutant	
BclI	 BClI.down.new	 BClI.up.WT.new	 BClI.up.MUT.new	
N363S	 N363.2/4F	 N363S.down.WT.new	 N363S.down.MUT.new	
RS120	 rs12086634.com.f	 rs12086634.wt.r	 rs12086634.mut.r	
RS84	 rs846910.com.r	 RS846910.wt.f	 RS846910.mut.f	
RS770	 rs7701443.gr.com.r	 rs7701443.gr.wt.f	 rs7701443.gr.mut.f	
RS296	 rs2963156.gr.com.r	 rs2963156.gr.wt.f	 rs2963156.gr.mut.f	
TthIII1	 rs10052957.TthIII1.com.f	 rs10052957.TthIII1.wt.r	 rs10052957.TthIII1.mut.r	
ER/EK	 rs6190.EREK.com.f	 rs6190.EREK.wt.r	 rs6190.EREK.mut.r	
	
Gel	Electrophoresis	
Gel	electrophoresis	was	used	to	analyze	primer-binding	efficiency,	in	order	to	first	optimize	the	
primer	sets,	and	then	subsequently	genotype	patients.		The	PCR	reactions	were	processed	
through	a	3%	gel	at	100	V,	which	ran	for	roughly	30	minutes.	The	gel	was	stained	with	ethidium	
bromide	so	bands	could	be	detected	under	the	UV	light	from	G:BOX	SYNGENE	(Appendix	G).	
	
	
	
	
	
Results	
PCR	optimization		
Using	the	annealing	temperature	calculated	by	the	selected	WASP	result	as	a	starting	point,	
various	PCR	trials	were	run	for	each	SNP	until	an	Optimized	annealing	temperature	was	
identified.	PCR	reactions	were	run	in	a	Bio	Rad	C1000	Thermal	Cycler.		As	seen	in	Table	3	below,	
six	of	the	eight	target	SNPs	were	originally	optimized.			
Table	3.	Optimized	PCR	Annealing	Temperature	for	each	SNP	
	
Unfortunately,	due	to	reasons	still	not	fully	
understood,	BclI,	N363S,	TthIII1,	and	RS12086634	were	
the	only	primers	that	continued	to	work	throughout	
the	entire	genotyping	process.	
	
	
	
	 	
Polymorphism	 Annealing	Temp	(°C)	
BcI1	 52°	
N363	 55°	
RS12086634	 52°	
RS846910*	 -	
RS7701443	 52°	
RS2963156	 55°	
TthIII1	 61°	
ER/EK*	 -	
*	Signifies	failure	to	optimize		
Genotyping	of	Participants	
 
Genotyping	was	determined	based	on	the	method	described	in	the	Gel	Electrophoresis	section.	
Appendix	G	has	additional	agarose	gel	electrophoresis	results.		Figure	9	demonstrates	what	the	
genotyping	looked	like.		A	complete	account	of	individual	genotype	and	relevant	clinical	
information	is	in	appendix	H.	
	
Prevalence	of	the	SNPs	
Based	on	the	genotyping	results,	the	total	genotypic	and	allelic	frequencies	of	both	the	random	
and	the	bariatric	populations	could	be	compared	for	each	optimized	SNP.	
Figure	9.	An	aggregation	of	the	gel	electrophoresis	results	for	each	of	the	four	fully	optimized	SNPs.	This	figure	includes	subjects	25,	26,	27,28,	29	&	31	from	the	Union	College	student	population	
Table	4.	The	genotypic	and	allelic	break	down	for	all	successful	Ellis	patients	and	Union	students	
	
	
	
	
	
	
	
	
There	was	
no	
significant	
difference	
between	the	random	and	bariatric	population	for	the	genotypic	and	allelic	frequencies	of	
NR3C1	hypersensitivity	SNPs	(BclI	and	N363S).	However,	TthIII1,	a	GR	resistance	SNP,	was	
present	at	a	much	lower	allelic	frequency	in	the	bariatric	population	compared	to	the	random	
population	tested	and	the	frequency	listed	in	the	literature.		In	addition,	the	RS12086634	SNP,	
associated	with	overactive	11ß-HSD	I	enzyme	activity,	was	present	at	a	much	higher	frequency	
in	the	bariatric	population	compared	to	the	random	population.		
	
	 	
	
Discussion:	
	 In	this	study,	we	hypothesized	that	metabolic	syndrome	may	be	a	cushingoid-like	state	
with	normal	cortisol	levels,	accompanied	by	GR	hypersensitivity	and/or	overactive	11ß-HSD	I.		
Based	on	our	collected	allelic	frequencies,	we	found	that	the	bariatric	population	not	only	had	
increased	peripheral	conversion	of	cortisone	into	the	active	metabolite	cortisol,	but	it	also	
lacked	cortisol	resistance	polymorphisms.		These	allelic	frequencies	support	our	hypothesis	that	
cortisol	signaling	and	regulation	is	a	contributing	factor	to	morbid	obesity,	and	can	potentially	
bridge	the	mechanistic	gap	between	Cushing’s	Syndrome	and	Metabolic	Syndrome.			
There	is	plenty	of	statistical	analysis	that	still	needs	to	be	done	to	the	collected	data,	
which	will	aid	in	strengthening	conclusions.		First,	haplotype	analysis	must	be	performed	
extensively.		As	of	now,	all	that	is	known	is	the	overall	allele	frequencies	of	the	four	optimized	
SNPs.	Haplotype	analysis	is	necessary	in	order	to	examine	whether	certain	SNP	combinations	
have	larger	impacts	on	HPA	axis	dysregulation	than	they	would	independently.		It	will	be	helpful	
to	compare	allelic	frequencies	with	metabolic	parameters	and	bariatric	surgery	success.	
In	addition,	to	adding	haplotype	analysis,	we	must	broaden	our	approach	by	not	just	
examining	more	SNPs	within	the	current	areas	of	study	(NR3C1	and	11ß-HSD	I),	but	looking	to	
see	how	other	receptors	and	genes	and	signaling	factors	play	a	role.		The	MR	is	very	much	
impacted	by	glucocorticoid	signaling	and	plays	a	role	in	HPA	axis	regulation.		Studies	by	Spijker	
et	al.,	(2009)	suggest	that	there	is	a	connected	pathophysiology	between	the	GR	and	the	MR	
involved	in	glucocorticoid	signaling.	
	 The	MR	becomes	even	more	relevant	when	this	research	project	begins	genotyping	
depressed	individuals,	for	cerebral	MRs	are	not	guarded	by	11ß-HSD	II,	and	therefore	play	a	
stronger	role	impacting	neuropsychology	compared	to	metabolism.	
	 There	are	two	other	interesting	areas	to	explore	that	could	reveal	relevant	information	
about	HPA	axis	regulation.		Considering	that	only	the	free,	unbound	glucocorticoids	can	have	a	
biological	effect,	levels	of	CBG,	may	influence	cortisol	bioavailability1.		Severe	CBG	mutations	
have	been	associated	with	both	chronic	fatigue	syndrome	(CFS)	and	increased	fat	
distribution28,29.		There	was	also	a	correlation	with	hypocortisolism,	a	classic	culprit	for	CFS29.		
The	second	new	area	to	introduce,	which	would	improve	this	study,	is	to	look	more	in	
depth	at	glucocorticoid	receptor	signaling.		Clearly,	a	variety	of	factors	including	glucocorticoid	
concentrations,	local	glucocorticoid	availability,	HPA	regulation,	genetics/relevant	
polymorphisms,	and	NR3C1	receptor	affinity	all	affect	glucocorticoid	sensitivity.		Another	
interesting	factor	are	disruptions	in	glucocorticoid	signaling.	Major	depression	is	often	
characterized	by	HPA	axis	overactivity	and	high	levels	of	cytokines17.		In	fact,	inflammation	is	a	
key	feature	in	some	depression	and	obesity	cases.		A	study	with	35	healthy	men	and	women	
identified	a	shared	pathophysiology	of	immune	dysregulation	in	both	depression	and	
obesity8.		How	is	this	possible	if	cortisol,	in	addition	to	cortisol’s	many	effects	mentioned	
earlier,	is	also	acts	as	a	strong	anti-inflammatory?	It	has	to	due	with	the	way	cytokine	signals	
access	the	brain	and	interact	with	pathophysiologic	pathways	(i.e.	disrupt	GR	activity)	relevant	
to	mood	regulation17.			
	
Cheng	et	al.,	(2013)	discovered	that	inflammation	regulated	by	GC-GR	is	the	
pathophysiological	link	between	depressive	symptoms	and	obesity.	They	identified	a	peripheral	
loop	of	bidirectional	association	within	the	GR	signaling	pathway	when	in	the	presence	of	
inflammation.	The	peripheral	blood	monocytes	of	stressed	individuals’	contained	lower	levels	
of	glucocorticoid	response	element	expression,	but	an	increase	in	inflammatory	transcription	
factors8.	Varying	cytokines	impacted	the	HPA	axis,	disrupting	GR	secretion,	GR	translation	and	
GR	posttranslational	modifications.	Therefore,	depression	induces	inflammation	dysregulation	
via	GR	insensitivity	to	glucocorticoids	on	immune	cells,	which	results	in	an	inflammation	
dysregulation	that	in	turn	promotes	further	glucocorticoid	insensitivity8.		
	
	
	
	
Figure	617.	Cytokine-Glucocorticoid	Receptor	signaling	pathways	interactions	These	simplified	signal	transduction	interactions	demonstrates	the	complex	inhibitory	and	induction	relationships	between	cortisol,	the	GR	and	cytokines.			
Due	to	the	feasibility	of	acquiring	a	metabolic	syndrome	patient	population	compared	to	
a	depressed	patient	population,	this	study	was	first	initiated	on	a	bariatric	population.	Because	
of	the	connectedness	of	depression,	specifically	MDD,	with	dyslipidemia,	insulin	resistance	and	
hypertension,	we	can	extend	this	exact	research	method	to	depression.	The	Institutional	
Review	Board	at	Albany	Medical	College	has	approved	that	very	project,	which	will	hopefully	
begin	the	summer	of	2017.	
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Appendix	
A- Ellis	IRB	Form	and	approval	
B-  ELLIS HOSPITAL 
C-  INSTITUTIONAL REVIEW BOARD 
D-  APPLICATION FOR RESEARCH PROJECT 
E-   
F- Project: 
G- Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly 
Obese Patients 
H-  
I- Name, Title and Position of Principal Investigator (s):  
J- Anne Jones, RN 
K-  
L- Co-Investigators:  
M- Brian D. Cohen, PhD, Senior Lecturer, Union College Dept. of 
Biological Sciences 
N-  
O- Purpose of Project: 
P- To characterize the presence of glucocorticoid receptor polymorphisms 
associated with obesity in patients undergoing bariatric surgery 
procedures. 
Q-  
R- Describe Population for Study: 
S- The population for the study will be patients who are preparing for or 
have undergone bariatric surgery procedures for treatment of morbid 
obesity. 
T-  
U- Has  IND # been obtained, if applicable:    ___       IND# _________ 
V- Has NDE # been obtained, if applicable:            NDE#_________ 
W-  
X-  
Y- Probable Time Project May Take: 
Z- Initial studies are projected for 5 months but may extend depending on 
enrollment rate 
AA-  
BB- Probable Starting Date : 
CC- 1/5/14 
DD-  
EE- Potential Hazards and Precautions: 
FF- There are no potential hazards or precautions for the subjects or the 
investigators 
GG-  
HH- Potential Inconveniences or Discomforts to Subjects and Other 
Pertinent Clinical Information: 
II- Subjects will be asked to swish a sterile saline solution in their mouths 
for 30 seconds which some subjects may find unpleasant.   
JJ-  
KK- Estimated Number of Human Subjects Required: 
LL- We are currently targeting 100 subjects as a starting group, although 
we are hoping for a larger subject pool if possible 
MM-  
NN- Estimated Duration of Study: 
OO- Initial study is projected for 5 months, although extension of the 
study may be requested depending on the rate of enrollment of subjects. 
PP-  
QQ- Have You Discussed This Protocol With Other Practitioners 
Affected?   
RR- YES___      NO_X__       If Yes, with Whom? 
SS-  
TT-  
UU- Approval Must be Obtained from the Director of Pharmacy for 
Protocols 
VV- Involving Investigational New Drugs Before IRB Review.  
WW-  
XX- Not Applicable 
YY-         
                                 Director of Pharmacy 
ZZ-  
AAA- Approval Must be Obtained from the Director of Materials 
Management (Purchasing) for Protocols Involving Non-Approved 
Devices or the Purchase of New Devices Before IRB Review. 
BBB-  
CCC- Not Applicable 
DDD-         
           Director of 
Materials Management 
EEE-  
FFF- Source of Funds: 
GGG- Materials for isolating and analyzing patient DNA will be 
provided from the Union College Student Research Grant Fund and the 
Union College Faculty Research Fund 
HHH-  
III- Facilities to be Utilized: 
JJJ- DNA sample, demographic, and clinical information collection will be 
done at the Ellis Bariatric Offices  
KKK- DNA analysis will be done at Union College in Dr. Cohen’s 
research lab. 
LLL-  
MMM- Have you or are you in the process of undertaking training 
or certification in the area of Human Subject Research? 
NNN- Yes _____ No__X___ 
OOO-  
PPP- If Yes, Please provide a copy of the certification with this application. 
QQQ-  
RRR-  
SSS- Do you have any Relationship with the Study Sponsor, Manufacturer 
of the Device or Medication in which you are investigating that should 
be disclosed?  
TTT- Yes _____ No___x__ 
UUU-  
VVV- If Yes, please explain: 
_______________________________________________ 
WWW-  
XXX- Note:  Research that has been approved by the IRB may be 
subject to further appropriate review by Hospital administration if Ellis 
Hospital’s resources are to be utilized in this study. 
YYY-  
ZZZ- Signature of Department Chair/Division 
Chief:__________________________ 
AAAA-  
BBBB- Ten	(10)	copies	of	the	Protocol	
and/or	Informed	Consent	need	to	be	delivered	(electronic	copy	
preferred)	to	the	IRB	Chair,	Michael	Pasquarella,	A-Ground,	Ellis	
Hospital,	at	least	One	Week	prior	to	the	meeting. 
CCCC- 	
	
	
	
	
	
	
 
  
1101 Nott Street    Schenectady, New York 12308   Phone: (518) 243-4011    www.ellismedicine.org 
  
December 23, 2014 
Anne Jones RN 
Brian D Cohen PhD 
Ellis Medicine Bariatric Care Center 
2125 River Road Suite #302 
Niskayuna, NY 12309 
  
Re:  Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly Obese Patients 
  
Dear Ann and Dr. Cohen 
Thank you for attending the December 18, 2014 meeting of the Institutional Review Board. Under 
full board review the protocol, informed consent (with changes) and other materials presented for 
the above mentioned study were approved.  The study was approved for 2 years with an interim 
report due at the June 2015 IRB meeting.  As a reminder, no additional changes may be made to 
this project without first submitting the changes to the IRB for review.  Any inquiries or 
unanticipated problems must also be promptly reported. 
Thank you for your continued interest in medical research. 
Sincerely, 
  Michael V. Pasquarella 
Michael V. Pasquarella Pharm.D., R.Ph. 
Chairperson 
Institutional Review Board 
  
cc: Pat Biggica 
 
 
 
 
 
B-	Ellis	Participant	Informed	Consent	Informed	Consent	Form 	The	purpose	of	this	research	project	is	to	look	for	a	correlation	between	polymorphisms	of	the	glucocorticoid	receptor	(variations	in	the	DNA	sequence	of	the	natural	receptor	for	the	hormone	cortisol)	and	clinical	manifestations	of	obesity	and	related	comorbidities	such	as	elevated	blood	sugar,	blood	pressure,	increased	waist/hip	circumference	ratio,	and	altered	serum	lipid	profiles.				Agreeing	to	participate	in	this	study	means	that	you	will	allow	the	testing	of	your	DNA	for	the	purposes	of	 identifying	receptor	variations	and	you	are	agreeing	for	relevant	medical	data	to	be	provided	to	the	researchers	to	compare	with	the	receptor	variations.	You	will	not	receive	information	about	your	individual	results	from	this	study.		Your	DNA	will	not	be	used	for	any	other	purpose	or	analyzed	in	any	other	way.		After	2	years,	your	DNA	sample	will	be	destroyed.		Your	decision	 about	whether	or	not	 to	participate	will	 not	 affect	 your	 treatment	by	Ellis	Bariatric	Medicine.		You	will	not	be	compensated	for	your	participation	in	the	study.		If	you	decide	to	participate	you	will	be	asked	to	perform	a	mouthwash	with	sterile	saline	that	will	allow	us	to	recover	cells	from	inside	your	cheek.		Some	people	find	the	salty	taste	of	the	saline	wash	a	little	unpleasant	but	should	provide	no	significant	discomfort	or	risk	for	you.			Identification	of	which	genetic	variant(s)	of	this	gene	you	have	will	not	affect	your	treatment	in	 any	way.	 	As	 information	 is	 gathered	about	 the	 relationship	between	variations	of	 the	cortisol	 receptor	gene	and	obesity	 (and	 related	diseases),	 it	may	eventually	help	 identify	opportunities	for	complimentary	therapies	for	obesity,	but	this	is	beyond	the	scope	of	the	present	study.	 	Currently	we	are	strictly	interested	in	determining	if	there	is	a	connection	between	this	gene	and	obesity	(and	related	diseases)	and	any	discovery	will	not	affect	your	treatment	plan.		Your	DNA	 sample	will	 be	 coded	with	 your	 patient	 identification	 number	 instead	 of	 your	name	before	it	is	given	to	researchers	at	Union	College	for	DNA	analysis.		The	researchers	will	also	be	given	access	anonymously	to	relevant	medical	information	from	your	records	required	to	complete	the	study.		Records	given	to	Union	College	researchers	will	only	have	your	patient	ID	number	and	not	your	name.		Relevant	medical	information	will	include	but	not	strictly	be	limited	to:	1. Your	weight	before	you	began	treatment	2. Your	height	3. Your	waist	to	hip	ratio	or	waist	circumference	(where	available)	before	you	began	treatment	4. Fasting	blood	sugar	5. Serum	triglycerides	
6. Serum	LDL	and	HDL	7. Blood	pressure	8. Related	medications	that	you	are	taking	that	might	affect	these	measures	9. Treatments	you	receive	at	Ellis	Bariatric	such	as	medications	and	surgical	procedures		Your	DNA	sample	will	be	kept	in	the	laboratory	of	Dr.	Brian	Cohen	at	Union	College	and	will	only	be	accessible	 to	him	or	 to	his	 student	 researchers	working	on	 this	 research	project.	Similarly,	relevant	medical	information	made	available	to	Dr.	Cohen	will	only	be	available	to	him	or	his	student	researchers	and	will	not	be	accessible	to	anyone	else	at	Union	College.				Although	we	do	not	anticipate	making	any	discoveries	that	would	alter	your	care	or	cause	you	to	wish	to	drop	out	of	the	study,	if	any	such	discoveries	are	made	the	medical	staff	of	Ellis	Bariatric	will	contact	you	and	give	you	the	option	to	withdraw	from	the	study.		Choosing	to	withdraw	from	the	study	will	in	no	way	affect	your	care	as	a	patient	of	Ellis	Bariatric.		We	anticipate	that	more	than	100	patients	will	be	a	part	of	the	study	and	the	more	patients	that	are	included,	the	more	significant	any	findings	will	be.				If	 you	have	any	questions,	please	ask	Anne	 Jones,	RN,	CBN,	at	Ellis	Bariatric	or	Dr.	Brian	Cohen,	Union	College.	Their	contact	information	can	be	found	below.		You	will	be	asked	to	sign	one	copy	of	this	informed	consent	form	and	will	be	given	a	copy	to	keep	for	your	records.		The	 choice	 to	 be	 in	 this	 study	 and	 to	 stay	 in	 this	 study	 is	 strictly	 voluntary.	 	Refusal	 to	participate	will	involve	no	penalty	or	loss	of	benefits	which	you	are	otherwise	entitled.	You	may	discontinue	your	participation	at	any	time	with	no	penalty	or	loss	of	benefits	which	you	are	otherwise	entitled.	 	If	you	wish	to	leave	the	study,	please	contact	 	Ms.	Anne	Jones	and	inform	her	that	you	wish	to	withdraw	from	the	study.		You	will	be	asked	to	sign	a	written	form	indicating	your	desire	to	withdraw.	Ellis	Bariatric	will	then	inform	Dr.	Cohen	of	your	ID	number	and	your	DNA	sample	will	be	destroyed	and	your	relevant	medical	information	will	be	removed	from	the	data	set.		Thank	you	for	considering	being	a	part	of	 this	research	study.	 	 If	you	have	any	questions	before	participating	or	at	any	time	during	the	study,	please	do	not	hesitate	to	contact	us.		Anne	Jones,	RN,	CBN	Ellis	Bariatric	Medicine	jonesa@ellismedicine.org	518-831-7030	
Brian	D.	Cohen,	PhD	Union	College	cohenb@union.edu	518-388-8018	Michael	Pasquarella,	PharmD,	RPh	Chair,	Institutional	Review	Board	Ellis	Hospital	pasquarellam@ellismedicine.org	518-243-1818	
 	
1. I	have	been	informed	about	the	purpose	of	this	genetic	test	and	experimental	research	project.		2. I	understand	that	I	will	not	receive	the	results	from	the	testing.		3. I	have	been	informed	as	to	who	may	have	access	to	my	biological	sample,	and	that	the	laboratory	may	retain	any	leftover	sample	until	the	end	of	the	study,	at	which	point	it	will	be	destroyed.		4. I	 have	 read	 the	 material	 provided	 and	 this	 consent	 form	 in	 full.	 My	 questions	 have	 been	answered	to	my	satisfaction.		5. I	consent	to	provide	a	sample	for	genetic	testing	and	to	have	relevant	medical	data	provided	anonymously	to	the	researchers.		6. I	 understand	 that	my	participation	 is	 completely	voluntary	and	 I	may	withdraw	at	 any	 time	without	affecting	my	care	as	a	patient	of	Ellis	Bariatric.				 ______________________________________________________________________________	
Signature	 																																																																				Date	 	 		
	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
 	
	
C	–	DNA	Extraction	Protocol	
Isolation	of	Crude	Human	Genomic	DNA	samples	suitable	for	PCR			
	
	 The	source	of	DNA	that	you	will	use	for	PCR	reactions	next	week	will	be	your	cheek	cells,	which	will	be	obtained	by	a	sterile	
saline	mouthwash.		The	cells	are	collected	by	centrifugation	and	resuspend	in	a	solution	containing	the	resin	"Chelex",	which	binds	
metal	ions	that	would	otherwise	inhibit	the	PCR	reaction.		The	cells	are	then	lysed	by	boiling,	and	centrifuged	to	remove	cell	debris	
and	the	Chelex	resin.	The	result	is	a	crude	genomic	DNA	prep	that	is	"good"	enough	for	PCR!		
	
You	should	have	the	following	materials	available	before	you	start:	
	
Materials:	
	
Microfuge	tubes	and	racks;	micropipettors	and	tips		
One	15	ml	plastic	“Blue-top”	tube	
One	Non-sterile	(but	unused)	plastic	“Dixie”	cup	
One	plastic	transfer	pipette		
Labelled	Waste	container	for	“spit”	waste	
Microfuge	tube	containing	1.2	ml	of	10%	Chelex	(labeled		“Chelex")		
		
Shared	Materials:	
	
Clinical	Table-top	Centrifuge	for	pelleting	cells	
Boiling	water	baths	with	“floatie”	for	boiling	samples	
Microfuge	
	
1)		Get	a	boiling	water	bath	ready	for	use	in	step	8.		Fill	up	an	ice	bucket	halfway	using	crushed	ice	obtained	from	the	Biology	
“autoclave	room”	on	the	third	floor.			
	
2)		Label	a	15	ml	tube	(blue-top)	with	your	initials	on	the	top	and	the	side	of	the	tube,	and	pipette	(or	carefully	pour)	10	ml	of	sterile	
saline	into	the	tube.	Label	a	new	microfuge	tube	with	your	initials,	also	on	the	top	and	side	of	the	tube.	
	
3)		Pour	all	of	the	saline	solution	into	your	mouth	(don't	swallow	it!),	and	vigorously	swish	for	15	seconds.		Carefully	expel	the	fluid	
into	a	plastic	Dixie	cup,	and	then	pour	the	liquid	back	into	the	15	ml	tube	and	reclose	the	cap.	
	
4)		Place	your	tube	in	a	clinical	centrifuge	balanced	against	another	tube	opposite	it	in	the	rotor.		Try	and	fill	up	the	rotor	if	you	can	
with	tubes	from	other	members	of	the	class.		Centrifuge	for	10	minutes	at	1,000	X	g	for	10	minutes	to	pellet	the	cells.	
	
5)		After	the	spin	is	over,	use	a	transfer	pipette	to	pipette	off	as	much	of	the	supernatant	as	possible	into	the	labeled	waste	
container	(we'll	autoclave	this	later).		Pipette	off	the	liquid	so	that	the	cells	remain	with	only	a	minimal	amount	of	liquid	(approx	200	
µL).		You	might	have	to	briefly	(1	min.)	spin	the	tube	again	if	the	cells	get	dislodged	from	the	side/bottom	of	the	tube	during	this	
process.		Resuspend	the	cells	in	the	minimal	volume	of	remaining	supernatant	by	vortexing,	and	then	transfer	the	whole	volume	
using	the	same	plastic	transfer	pipette	to	a	new,	labelled	microfuge	tube.	Vortex	this	tube	containing	the	cells	for	5-10	seconds,	
making	sure	that	there	are	no	clumps	of	cells	remaining.		
	
6)		Resuspend	the	Chelex	beads	(in	the	microfuge	tube	labeled	"10%	Chelex")	by	vortexing	for	10	seconds.		Before	the	beads	have	
 	
had	a	chance	to	settle,	pipette	500	µL	of	Chelex	solution	into	your	microfuge	tube	containing	the	cells.			
	
7)		Resuspend	the	cells	in	the	Chelex	by	vortexing	for	10	seconds.	Make	sure	that	no	cell	clumps	remain.		
	
8)		Incubate	the	microfuge	tube	containing	the	cells/Chelex	mixture	in	the	boiling	water	bath	for	10	minutes,	using	a	plastic	"floatie".		
Other	peoples'	tubes	will	also	be	boiled	at	the	same	time	in	the	water	bath,	so	make	sure	that	your	tube	is	labelled	well!	
	
9)		Remove	the	floatie	carefully	from	the	boiling	water	bath,	take	your	tube	and	incubate	it	on	ice	for	two	minutes.		Spin	the	tube	in	
a	microfuge	(max.	speed)	for	1	minute	to	pellet	the	Chelex	and	cell	debris	to	the	bottom	of	the	tube.	
	
10)		Using	a	200	µL	pipette,	carefully	transfer	200	µL	of	the	supernatant	(pipette	from	the	top)	to	a	new,	labeled	(with	your	initials)	
microfuge	tube.		Avoid	transferring	any	of	the	pelleted	cells	or	the	Chelex.	Discard	the	tube	containing	the	pellet.	YOUR	PREP	IS	
DONE	AT	THIS	POINT!	You	should	store	your	genomic	DNA	in	the	fridge	in	a	labeled	box	or	tube	rack.					
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 	
D-	Human	Subjects		
UNION COLLEGE HUMAN SUBECTS REVIEW COMMITTEE 
2016-2017 APPLICATION TO ENGAGE IN RESEARCH INVOLVING HUMAN SUBJECTS 
 
For full instructions, please visit http://bit.ly/hsrc 
 
Please type your responses in the fields provided.  The grey fields will expand if more space is needed.  When 
completed, please print and deliver to Joshua Hart, Chair of the Human Subjects Review Committee, Bailey 
Hall 302.  Emailed, hand-printed, or unsigned applications will be returned unreviewed.  Blue links can be 
followed by holding the “control” key and clicking. 
 
1a.  Name of student researcher (if applicable)  > Justin Salm  
 Box number  > 1826  
 Email address  > salmj@union.edu  
 Major > Biology 
 
1b. Name of student researcher (if applicable)  > Brianna Godlewski  
 Box number  > 703  
 Email address  > godlewsb@union.edu  
 Major > Biology  
 
2.  Name of faculty researcher or sponsor  > Brian Cohen  
 Office location  > Wold 220  
 Email address  > cohenb@union.edu  
 Department  > Biology  
 
3.  Title of project >  Prevalence of Polymorphisms in the stress related genes in an Undergraduate Population 
 
 
4.   Is this research funded?  > SRG funds requested for materials  
 If yes, by whom?  >   
 
5.  Approximate number of participants:  > 64  
 Approximate age range of participants:  > 18-21    
 Other important characteristics of participants (e.g., prisoners, minors, participants in poor mental or 
 physical health, etc.)  > None  
 
6. Where will the data be collected?  > Union College  
 
7.   If data will be collected at a location other than Union College’s campus, identify how you secured 
permission from the appropriate individuals at the other location(s).  Include this individual’s name and 
contact information.  > N/A  
 
8. How will participants be sampled, recruited, or otherwise enlisted?  > Participants will be BIO 225 Students  
    
 	
9. What rewards, payment, or other credit will be provided for participation, if any?  > None  
 
10. How will the anonymity of participants and/or the confidentiality of the data be ensured?  > The DNA samples 
will be given a random number and students will be asked to transfer the DNA into the new tube so that the tubes will not 
have any other identifying marks.  The number on the DNA sample will be correlated with the form containing information on 
whether the student has previously been diagnosed with depression and the students height and weight.  The form will have 
no identifying information other than the matching number for the DNA sample.  Once filled out, the student will fold the 
form, tape it shut, and hand it to their lab professor.  The lab professor will then give the completed forms and related saliva 
samples to the researchers.  
 
 
For the following items, indicate YES or NO.  If the answer is YES, please explain. 
 
11.   Is it reasonably possible that any of the participants will be placed at risk with regard to physical 
pain or discomfort, psychological stress or discomfort, or social injury (e.g., diminished reputation or 
damaged social or personal relationships)?  >  No  
 
12.   Will information that might affect participants’ willingness to participate be withheld from them 
prior to securing informed consent to take part in the research?  > No  
 
13. Will there be any coercion or penalties that might negate a participant’s freedom to refuse to 
participate in the study or withdraw from participation?  > No  
 
14. Will any of the researchers who will be conducting the study be placed at risk with regard to 
physical or psychological pain, discomfort, or harm?  > No  
 
15. Will any deception be involved?  If so, explain the nature of the deception, the need for the 
deception, and how risks from that deception will be mitigated. > No  
 
16. Will topics or questions about depression or about thoughts of or attempts to engage in of self-
injury or suicide be included?  > Yes.  For part a of this project, the goal is to establish a correlation between 
specific gene polymorphisms in an undergraduate  student population and depression.  For this research, it is 
imperative to know whether the DNA sample belonged to an individual with depression.  However, due to the 
precautions explained in question 10 above, this information can only be related back to the DNA sample, not the 
student.    
 
 
For the following items, indicate YES or NO.  If the answer is NO, please explain. 
 
17. Will all promises and commitments made to the participants regarding their participation be duly 
honored by the researcher?  > Yes  
 
18. Will it be made clear from the onset of the study that participants are free to withdraw from the 
study at any time?  > Yes  
 
 	
19. Immediately following their participation, will all participants be provided with a complete 
explanation (debriefing) of the nature of the study so as to eliminate any possible misconceptions about 
its purpose and to eliminate any stress or discomfort experienced by participants? > Yes  
 
20. If payment is offered, immediately following their participation, will all participants be provided 
with payment as promised (e.g., credit for course, gift certificate, etc) ? > Yes  
 
 
21.  The United States Government, via 45CFR46.116(d), states that informed consent must be obtained from 
participants unless, among other criteria, it is not practicable to do so.   
 
If you do plan to obtain informed consent, please indicate how, whether it be an informed-consent form, 
a clickable button on a Website, or via other documentable means:  > An informed-consent form  
 
If you do not plan to obtain informed consent, please explain how your study meets each of the four 
criteria for waiving this requirement as set forth by 45CFR46.116(d).  > N/A  
  
 
22 (OPTIONAL).  In addition to the specific explanations that may have been provided with the responses to 
items #11 through #21, you are welcome to provide any further comments that might help the Committee 
determine whether the proposed research is likely to produce benefits so significant as to outweigh any 
questionable or risk-producing research procedures.  >   
 
 
 
 
PLEASE ATTACH THE FOLLOWING APPENDICES. 
 
APPENDIX W:  Briefly explain the purpose of the research and provide a general description of the methods to 
be employed (200 words should be sufficient). 
The	research	attempts	to	examine	the	presence	of	specific	polymorphisms located in the glucocorticoid receptor, the 
mineralocorticoid receptor and the enzyme 11-ß HSD1 to	establish	a	relationship	between	the	relevant	polymorphisms	
and	depression	(part	a)	or	obesity(part	b).		To	do	so,	cells	extracted	from	patients’	cheek	cells	can	be	tested	for	the	
presence	of	the	polymorphisms	using	a	PCR	method,	and	data	can	be	collected	on	their	height	and	weight	to	find	the	
patients’	BMIs.	The	student	population	represents	a	control	group	that	could	then	be	compared	to	a	group	of	depressed	
patients	(part	a)	and	morbidly	obese	bariatric	patients	(part	b)	to	establish	a	difference	in	the	prevalence	of	the	
polymorphisms	in	the	different	populations.	Because	cheek	cell	samples	are	already	being	collected	in	BIO	225	as	part	of	
an	experiment,	we	would	simply	ask	the	students	consent	to	use	their	DNA	samples	for	our	experiment	as	well	as	
provide	whether	they	have	previously	been	diagnosed	with	depression	and	their	height	and	weight. 
 	  
 	
APPENDIX X:  Provide a copy of the informed consent materials you plan to administer to participants (unless 
you have made a case for not using one in #21.  Whether you use the sample form found here or the OHRP 
checklist found here, please ensure that your form contains all the elements called for by OHRP. 
 
 
INFORMED CONSENT FORM 
 
 
Our names are Brianna Godlewski and Justin Salm and we are students at Union College in Schenectady, NY.  We are 
inviting you to participate in a research study.  Involvement in the study is voluntary, so you may choose to participate or 
not.  Participation in the study will not affect your grade in BIO225. Your instructor will not know if you have 
participated or not.  A description of the study is written below. 
 
Our research is interested in determining if there is a relationship between variations in sequences of genes associated 
with stress responses and the prevalence of obesity and depression. You will be asked to provide access to the DNA 
sample that you generated for your BIO225 lab and ask you to answer a few questions including your height and weight 
and if you have ever been diagnosed with depression.  If you choose to participate in the study, we will ask you to put 
your DNA from lab into a new tube labeled with an arbitrary number and also to fill out a separate form marked with the 
same number.  This will take approximately 5 minutes. There are no foreseeable risks to taking part in this study. If you 
no longer wish to continue, you have the right to withdraw from the study, without penalty, at any time.   
 
Your responses will be anonymous: the arbitrary number will not be connected to you in any way so we will not be 
able to identify who filled out each form or whose DNA is being analyzed. 
 
All DNA samples collected will be destroyed after analysis, no later than 7/1/17. 
 
By signing below, you indicate that you understand the information above, and that you wish to participate in this research 
study. 
 
 
__________________________________  ________________________________ 
 __________________ 
Participant Signature    Printed Name     Date 
		  
 	
APPENDIX Y:  Provide a copy of all materials to be used in your study.  If an interview procedure is to be 
used, a detailed list of the types of questions that will be asked should be described.  If participants will be 
exposed to any stimuli, copies of those stimuli should be presented.  In the case of oral presentations, a 
transcript is sufficient.  To be clear: anything a participant will read, see, be asked, or answer needs to be 
included here. 
 
Instructions:  
1. If you choose to participate, please sign the informed consent form. 
2. Regardless of your decision to participate, please fold over the informed consent form, tape it closed, 
and return it to your instructor. This way neither your instructor nor your peers will be able to tell if you 
have chosen to participate. 
3. Please transfer your DNA to the new tube, regardless of whether or not you choose to participate in the 
study. 
4. If you choose to participate in the study, please complete the form below. If you choose not to 
participate in the study, do not complete the form below. 
5. Regardless of your decision to participate, please fold the form over, tape it closed and return this form 
and your DNA to your instructor.  This way neither your instructor nor your peers will be able to tell if 
you have chosen to participate. 
6. After class we will review the forms and keep only those samples where the form has been completed. 
 
 
Sample Number:___________________________ 
 
Height (ft and in) _______________     Weight (lbs) _______________ 
 
Have you ever been diagnosed with depression? (Y/N)  ________
 	
 
	
APPENDIX Z:  Provide a copy of the debriefing to be presented to participants, either in 
text or orally.  A debriefing statement is a statement presented to participants after their 
participation.  It should provide some information about the research study in which they 
just participated.  It need not provide detailed discussions to include literature reviews or 
full hypotheses, but it should provide the participants with at least a basic understanding 
of what the research is about.  If it is not feasible to provide a debriefing, please explain 
why.  
 
Because we will not know which students have chosen to participate, we do not intend to 
provide a debrief.   
	
CERTIFICATION:  I/we certify that: 
  
The statements herein are factual to the best of my/our knowledge; 
I/we have described our methods and materials accurately and completely; 
I/we have not begun data collection in any way and will not do so until given HSRC approval; 
If the proposal is approved, I/we will not make any modifications to the study until receiving additional HSRC 
approval; 
I/we understand that the approval, if granted, expires one year from the initial approval date. 
  
                                                                                                                                                                          
____________________________________ ________________________________ 
Student researcher (if applicable)         date             Faculty researcher/advisor        date 
 
 
____________________________________  
Student researcher (if applicable)         date              
	
 
 
 
 
 
 
 
 
 
 
 
 
	
 	
E-	WASP	Results	
i.	N363S	
AS Primer Picking Result for SNP2015-01-22 
  
Input sequence 5':  
  
ATTAAGGATAATGGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAA
GTGAAAACAGAAAAAGAAGATTTCATCGAACTCTGCACCCCTG 
GGGTAATTAAGCAAGAGAAACTGGGCACAGTTTACTGTCAGGCAAGCTTTCCTGGA
GCAAATATAATTGGTAATAAAATGTCTGCCATTTCTGTTCATGG 
TGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCCCTTT
CTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCA 
ATTCCCGTTGGTTCCGAAA[A/G]TTGGAATAGGTGCCAAGGATCTGGAGATGACAAC
TTGACTTCTCTGGGGACTCTGAACTTCCCTGGTCGAACAGTT 
TTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCAGATGTAAGCTCTCCTCCATCC
AGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTCTGCC 
TGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGCT
GTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTA 
CCTATGTGCTGGAAGGAATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCC
AGCATGCCGCTATCGAAAATGTCTTCAGGCTGGAATGAACCTG 
GAAGCTCGAAAAACAAAGAAAAAA 
Sequence Size: 720 
  
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              100.0 
Max Self Complementarity: 8.0 
Max 3' Complementarity:   3.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'No' 
Mispriming Filtering: 'No' 
  
Oligo 1 :                                                       Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Forward Primer 5': 
ATTCCCGTTGGTTCCGAATA                301     20     61.41     45.00     5.00     2.00 
Mutant Forward Primer 5': 
ATTCCCGTTGGTTCCGAATG                  301     20     64.11     50.00     5.00     2.00 
Common Reverse Primer 5': 
GCTTACATCTGGTCTCATGC                  441     20     55.83     50.00     4.00     2.00 
Product Size: 141 
  
 	
-------------------------------------------------------------------------------------- 
  
Oligo 2 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
TTCCCGTTGGTTCCGAATA                 302     19     61.21     47.37     5.00     2.00 
Mutant Forward Primer 5': 
TTCCCGTTGGTTCCGAATG                   302     19     64.06     52.63     5.00     2.00 
Common Reverse Primer 5': 
TTACATCTGGTCTCATGCTG                  439     20     54.65     45.00     4.00     2.00 
Product Size: 138 
  
-------------------------------------------------------------------------------------- 
  
Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
TCCCGTTGGTTCCGAATA                  303     18     59.85     50.00     5.00     2.00 
Mutant Forward Primer 5': 
TCCCGTTGGTTCCGAATG                    303     18     62.86     55.56     5.00     2.00 
Common Reverse Primer 5': 
TTACATCTGGTCTCATGCTG                  439     20     54.65     45.00     4.00     2.00 
Product Size: 137 
  
-------------------------------------------------------------------------------------- 
  
Oligo 4 
:   N363S.new                                                    Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Reverse Primer 5': 
AGATCCTTGGCACCTATTCCATT             342     23     62.17     43.48     4.00     1.00 
Mutant Reverse Primer 5': 
AGATCCTTGGCACCTATTCCATC               342     23     62.67     47.83     4.00     0.00 
Common Forward Primer 5': 
ATACAGCATCCCTTTCTCAA                  242     20     54.87     40.00     3.00     1.00 
Product Size: 101 
  
-------------------------------------------------------------------------------------- 
  
Oligo 5 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
GATCCTTGGCACCTATTCCATT              341     22     61.38     45.46     4.00     1.00 
Mutant Reverse Primer 5': 
GATCCTTGGCACCTATTCCATC                341     22     61.89     50.00     4.00     0.00 
Common Forward Primer 5': 
AATACAGCATCCCTTTCTCA                  241     20     54.87     40.00     3.00     1.00 
Product Size: 101 
 	
  
ii.	TthIII1	
AS Primer Picking Result for rs10052957 
 
Input sequence 5':  
 
CTTACGGAATTTAATTGAAGAGATGAACTCCAGTGTGCCAGAAAGGACGTGAGATTTAGCATTATAATAATAACACAAT
TCTAACGAAAGTCAACATTTA 
TTGCGCATCTGCTGTCTGACAGACACTATTGAAAGTGTTTTATGCACAGTATCCTAAGTCTTTAGGTATGGCATTTACT
AATCTGTAACCCTGGGAACTT 
ATAATTACTACAAGAAATAGGATGAATCCCTATCTGAGTGGGAAGGTATTTGATTGTCTTAGAAGCAGAGGTGGAAATG
AAGGTGATGTATTCAGACTCA 
[A/G]TCAAGGCAAGGACCTGATCTATCTTGTCATAGCTTTATGTCCCACTCCTGGAACACAGCCCACTACATAGCAGG
CACCCAACAAATACATTACAG 
GGTTATAATAACATTGAGTCAACTAGTTAACTAGATGTAAAATCACTTTTACTGGGTTATTGTTGTGGCCAAATGGGTT
AATAAAAAGTGTACAGATAAC 
CCTCAAGATCCTCATTTTTATTGTTTTGTGTTTAAACATCTGAGTGCTCCCCCCACTTTTTTTTAAAATAAACTAGATT
AGATTCTTGATTGTATGTTCT 
TATAG 
Sequence Size: 601 
 
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              2.0 
Max Self Complementarity: 5.0 
Max 3' Complementarity:   3.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'Yes' with Max Product Size: 4000 
Mispriming Filtering: 'Yes' Form Human Library 
 
Oligo 1 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
AGATAGATCAGGTCCTTGCCTTGTT           325     25     62.71     44.00     5.00    
 1.00 
Mutant Reverse Primer 5': 
AGATAGATCAGGTCCTTGCCTTGTC             325     25     63.21     48.00     5.00  
   1.00 
Common Forward Primer 5': 
TGAACTCCAGTGTGCCAGAAA                 24     21     61.82     47.62     4.00   
  0.00 
Product Size: 302 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
-------------------------------------------------------------------------------
------- 
 
Oligo 2 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
GATAGATCAGGTCCTTGCCTTGTT            324     24     61.98     45.83     5.00    
 1.00 
 	
Mutant Reverse Primer 5': 
GATAGATCAGGTCCTTGCCTTGTC              324     24     62.48     50.00     5.00  
   1.00 
Common Forward Primer 5': 
GATGAACTCCAGTGTGCCAGA                 22     21     61.28     52.38     4.00   
  3.00 
Product Size: 303 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
-------------------------------------------------------------------------------
------- 
 
Oligo 3 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
ATAGATCAGGTCCTTGCCTTGTT             323     23     60.37     43.48     5.00    
 1.00 
Mutant Reverse Primer 5': 
ATAGATCAGGTCCTTGCCTTGTC               323     23     60.85     47.83     5.00  
   1.00 
Common Forward Primer 5': 
ATGAACTCCAGTGTGCCAGA                  23     20     59.26     50.00     4.00   
  3.00 
Product Size: 301 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
-------------------------------------------------------------------------------
------- 
 
Oligo 4 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
TAGATCAGGTCCTTGCCTTGTT              322     22     60.13     45.46     5.00    
 1.00 
Mutant Reverse Primer 5': 
TAGATCAGGTCCTTGCCTTGTC                322     22     60.63     50.00     5.00  
   1.00 
Common Forward Primer 5': 
ATGAACTCCAGTGTGCCAGA                  23     20     59.26     50.00     4.00   
  3.00 
Product Size: 300 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
-------------------------------------------------------------------------------
------- 
 
Oligo 5 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
AGATCAGGTCCTTGCCTTGTT               321     21     60.13     47.62     5.00    
 1.00 
Mutant Reverse Primer 5’: 
AGATCAGGTCCTTGCCTTGTC                 321     21     60.64     52.38     5.00  
   1.00 
Common Forward Primer 5': 
GAACTCCAGTGTGCCAGAAA                  25     20     58.85     50.00     4.00   
  0.00 
Product Size: 297 
 	
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
------------------------------------------------------------------------------ 
	
iii.	ER22/23EK	
 
AS Primer Picking Result for rs6190 
 
Input sequence 5':  
 
GGATTGCATTGTACTTTTAAATGTGGCATGCTGAATGGGAGCAGGGGACATGGCTTTTTATTCTGGAAGATAGAAACTA
CTCTTCTGGTAACAAAGAATT 
TGATTCGGAGTTAACTAAAAGGTTCATTTAACAAGCTGCCTCTTACTAATCGGATCAGGAAGATAATGTGACTTTAGAG
CTTATGATGTTTTCCCCCCGT 
TTTTGTTTTTTGTTTTGTAGTTGATATTCACTGATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCA
GCAGTGTGCTTGCTCAGGAGA 
[A/G]GGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAGGTTTCTGCGTCTTCACCCTCAC
TGGCTGTCGCTTCTCAATCAG 
ACTCCAAGCAGCGAAGACTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAAGC
AGTTTCACTCTCAATGGGACT 
GTATATGGGAGAGACAGAAACAAAAGTGATGGGAAATGACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCG
GGGGAAACAGACTTAAAGCTT 
TTGGA 
Sequence Size: 601 
 
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              2.0 
Max Self Complementarity: 5.0 
Max 3' Complementarity:   3.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'Yes' with Max Product Size: 4000 
Mispriming Filtering: 'Yes' Form Human Library 
 
Oligo 1 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
TAGAAGTCCATCACATCTCCAT              322     22     56.18     40.91     4.00    
 2.00 
Mutant Reverse Primer 5': 
TAGAAGTCCATCACATCTCCAC                322     22     56.70     45.46     4.00  
   0.00 
Common Forward Primer 5': 
AGGTTCATTTAACAAGCTGC                  120     20     54.71     40.00     5.00  
   3.00 
Product Size: 203 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
-------------------------------------------------------------------------------
------- 
 
Oligo 2 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
 	
AGAAGTCCATCACATCTCCAT               321     21     56.02     42.86     4.00    
 2.00 
Mutant Reverse Primer 5': 
AGAAGTCCATCACATCTCCAC                 321     21     56.55     47.62     4.00  
   0.00 
Common Forward Primer 5': 
AACAAAGAATTTGATTCGGA                  90     20     54.86     30.00     5.00   
  3.00 
Product Size: 232 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
-------------------------------------------------------------------------------
------- 
 
Oligo 3 
:  =ER/EK2                                               Pos.    Len.     Tm   
    GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
GAAGTCCATCACATCTCCAT                320     20     54.73     45.00     3.00    
 2.00 
Mutant Reverse Primer 5': 
GAAGTCCATCACATCTCCAC                  320     20     55.27     50.00     3.00  
   0.00 
Common Forward Primer 5': 
CAAAGAATTTGATTCGGAGT                  92     20     54.44     35.00     5.00   
  3.00 
Product Size: 229 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
-------------------------------------------------------------------------------
------- 
 
Oligo 4 
:                                                       Pos.    Len.     Tm    
   GC%   Self Any   Self End 
Wildtype Reverse Primer 5': 
AGTCCATCACATCTCCAT                  318     18     50.22     44.44     2.00    
 2.00 
Mutant Reverse Primer 5': 
AGTCCATCACATCTCCAC                    318     18     50.73     50.00     2.00  
   0.00 
Common Forward Primer 5': 
AAGAATTTGATTCGGAGTTA                  94     20     51.70     30.00     5.00   
  3.00 
Product Size: 225 
In-silico PCR Accepted: There is only one PCR product in the current human 
genome. 
------------------------------------------------------------------------------ 
 
iv.	BclI	
	
AS Primer Picking Result for SNP2015-01-23 
  
Input sequence 5':  
  
ACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCCCTTTCTCAACA
GCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCG 
 	
TTGGTTCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCT
CTGGGGACTCTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGG 
CTATTCAAGGTAAGATCAGTGTTTTTCTGTTTCTTAAGAATGGTACATTTAAGGTAGA
TTAATAGATGTAAATCTTCATTGATTTATATGTGTTCTCTAA 
AGATTCATGTGCTTTTTTATATGAATAAGTTTAAGTGGCCTTTTGAAAGTAGGAAAGG
TAGACAACCTAAGTGACATCTGTACGTAACCATTTCAGGTTT 
TTTCCTTAAATAGTGGTTTTCAGTATCCCATTGGCCAACGGTGAGGATTTTATTTAAC
ATTTTTAAAATAATGTTGCTCATTAACAGATATCTTAACGAA 
AAATTATATAAATTCAGGAGAGTATAATGTCTCATAATATCATATTGTGTTGTGCATG
GTCATTCAGCTGTTTTAGAATATGTTCTTATATTACAATAAA 
TGATACCCTTACTTACATAGTCAAAAGTTGTGCTGCCTTATTTGTAAATTCGTTAAGT
GTTAGCTTGAGATTAAAGAGTTAAAAGCAGAAGTACTAACAA 
AGAGCCCTATTCTTCAAACTGAATCTTCTGTTAAAGAATTTGAGTTTTGAAGTTGCTA
AAGCAATGCAGTGAACAGTGTACCAGACCATAGTATTAGACA 
CAGGTCTTGCTCACAGGGTTCTTGCCATAAAGTAGACAAGTTATGTCTGCTGAT[C/G
]AATCTCTTTAAGAGAGGAATTGGTGTCAACATGGTGCAAAA 
CAAAATTTTACGTTCAAATGTTCCTGCAAGTTCTCAAGTAGATAACTGATGGCCAAA
ATTGTTAAGCTTCAATTTTCAGCTTTCGTTTGATTTTTCTCTT 
TTTTTTACTCAGTCGTTTATAAGCATACTGATATTTTTGTCTGACCCAAAAAGGTCAG
AAAATGGAATTATCAGAAAAAAGTTCTAAATGTAGATATACG 
TGTTGGTAGGGGTGAATTTCTCTACCCCGTAACCTCATCCCCAATTCAGATAAATGC
TAGGTTTTATATCCATTTTAGTTGTGAAGGAAAATATAAAAAT 
GTGGATTGTAGTGACACAAGATTGATTAATCAGCGGGTTTTTTTAAAAGAAGACATG
GTAGACAGTGATTTATTTGTATGTAACTATTGAAGTTTTTTCT 
TAAATGTTAGTGATATTCATCGTTCCCATTAACTAGTTATTCAGATTTTTGAAAATCCT
TTTTCTGTGAAAGCTATCCTAACCTGGAGGATGTCTCTTTT 
CTTTCCTCTGTACTTAAGAAGCTTTTCTTGTTAGGGAAATAATTTAGAATTAGATTTA
GGCTATGTTCTGTTCTTCTAAAAGGCTTAGTTGTCAAAAAAA 
AAAAAAAAAAAACCAAAAAACCTTGGTTCTTACATGTCTTAATGTGAACTACCTCCTA
ATCTATTGTTTAAATAATTATCCTTTATTTAGAAGAACACTA 
CTTCAACCTGAGTTGAAGGTTTAAAATCTTTTCAGTAAGGAGATTTGAGATCTTTATT
ATTGCATAAGCTGTTGTGTTTTAAATGCTAAAAGACATGCTG 
TGTTTTAAAATTTTCAATTGCAAATTTTTGGCAATAGAATTCGCATACTTGGTTTTCTT
AAAAGAGTTAAGTACGGTTGATTTGACTAAGCTATCTGTAG 
GAAACTCTTAAATTGATTTATAAAACATGTAATTATACAAAGAAAAATAAAACATCTTA
GGAAACTCTTGGGGATTATTAATGGATTTTGCCCTGATAAT 
CATCATGGCATGGTTTTCATTTTCCTTACTATAAAGAAAAGGCAAGGGACAAAACTT
ATT 
Sequence Size: 1956 
  
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 55.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              100.0 
Max Self Complementarity: 8.0 
Max 3' Complementarity:   5.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
 	
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'No' 
Mispriming Filtering: 'No' 
  
Oligo 1 :                                                       Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Forward Primer 5': 
AGTAGACAAGTTATGTCTGCTGACC           831     25     58.13     44.00     8.00     4.0
0 
Mutant Forward Primer 5': 
AGTAGACAAGTTATGTCTGCTGACG             831     25     59.10     44.00     8.00     4.
00 
Common Reverse Primer 5': 
AAATCAAACGAAAGCTGAAA                  989     20     55.26     30.00     4.00     0.00 
Product Size: 159 
  
-------------------------------------------------------------------------------------- 
  
Oligo 2 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
GTAGACAAGTTATGTCTGCTGACC            832     24     57.14     45.83     6.00     4.00 
Mutant Forward Primer 5': 
GTAGACAAGTTATGTCTGCTGACG              832     24     58.16     45.83     6.00     4.00 
Common Reverse Primer 5': 
AAATCAAACGAAAGCTGAAA                  989     20     55.26     30.00     4.00     0.00 
Product Size: 158 
  
-------------------------------------------------------------------------------------- 
  
Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
TAGACAAGTTATGTCTGCTGACC             833     23     56.23     43.48     6.00     4.00 
Mutant Forward Primer 5': 
TAGACAAGTTATGTCTGCTGACG               833     23     57.29     43.48     6.00     4.00 
Common Reverse Primer 5': 
AAATCAAACGAAAGCTGAAA                  989     20     55.26     30.00     4.00     0.00 
Product Size: 157 
  
-------------------------------------------------------------------------------------- 
  
Oligo 4 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
AGACAAGTTATGTCTGCTGACC              834     22     56.07     45.46     6.00     4.00 
Mutant Forward Primer 5': 
AGACAAGTTATGTCTGCTGACG                834     22     57.17     45.46     6.00     4.00 
 	
Common Reverse Primer 5': 
TTGACACCAATTCCTCTCTT                  884     20     54.73     40.00     4.00     0.00 
Product Size: 51 
  
-------------------------------------------------------------------------------------- 
  
Oligo 5 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Forward Primer 5': 
GACAAGTTATGTCTGCTGACC               835     21     54.85     47.62     6.00     4.00 
Mutant Forward Primer 5': 
GACAAGTTATGTCTGCTGACG                 835     21     56.01     47.62     6.00     4.00 
Common Reverse Primer 5': 
ACTTGAGAACTTGCAGGAAC                  935     20     54.53     45.00     4.00     2.00 
Product Size: 101 
  
-------------------------------------------------------------------------------------- 
  
v.	RS	12086634	
 
AS Primer Picking Result for rs12086634 
  
Input sequence 5':  
  
TGAGCAATCTCTCATTTAAGCCCCCCGTTACTTCAGAGACTACCCCCCAAAAATCTG
CAGCTAAGACTGATGCCATTTCTGCTGTATCACTGCAGGTGGT 
ATCCCACTGCCTGGAGCTTGGAGCAGCCTCAGCACACTACATTGCTGGCACCATG
GAAGACATGACCTTCGCAGAGCAATTTGTTGCCCAAGCAGGAAAG 
CTCATGGGTGAGGCTGTTTCTCTTACCTCCTCCTCTGAACTTTGCCCTTGGGGTCA
CCAAGAGCTTTTGGGAGGAGAATGGGAAAGGTATCAACCCCAGA 
[G/T]GATTTCTTAATATAGCCATCTCTTGCAGGAGGACTAGACATGCTCATTCTCAAC
CACATCACCAACACTTCTTTGAATCTTTTTCATGATGATAT 
TCACCATGTGCGCAAAAGCATGGAAGTCAACTTCCTCAGTTACGTGGTCCTGACTG
TAGCTGCCTTGCCCATGCTGAAGCAGAGCAATGGAAGCATTGTT 
GTCGTCTCCTCTCTGGCTGGTAAGTGGGACAGGGACATATGTGGAAGGTAGAAGA
AAAAAAAAAATGCCAGGGATGATGCCAGGCTCTGAAGTAGACATA 
AATTT 
Sequence Size: 601 
  
Primer Picking Parameters:  
Primer Size          Opt: 20 Min: 18 Max: 36 
GC%                  Opt: 50.0 Min: 20.0 Max: 85.0 
Tm                   Opt: 57.0 Min: 40.0 Max: 65.0 
Max Tm Diff:              100.0 
Max Self Complementarity: 8.0 
Max 3' Complementarity:   5.0 
Max PolyX in Primer:      3 
Number Primer Return:     5 
 	
Mismatch at the penultimate primer position: 'Yes' 
In-silico PCR Filtering: 'No' 
Mispriming Filtering: 'No' 
  
Oligo 1 :                                                       Pos.    Len.     Tm       GC%   Self 
Any   Self End 
Wildtype Reverse Primer 5': 
AAGAGATGGCTATATTAAGAAATTC           325     25     53.90     28.00     5.00     5.00 
Mutant Reverse Primer 5': 
AAGAGATGGCTATATTAAGAAATTA             325     25     52.46     24.00     4.00     2.0
0 
Common Forward Primer 5': 
TCTGCTGTATCACTGCAGGT                  78     20     56.96     50.00     8.00     4.00 
Product Size: 248 
  
-------------------------------------------------------------------------------------- 
  
Oligo 2 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
AGAGATGGCTATATTAAGAAATTC            324     24     52.48     29.17     5.00     5.00 
Mutant Reverse Primer 5': 
AGAGATGGCTATATTAAGAAATTA              324     24     50.98     25.00     4.00     2.00 
Common Forward Primer 5': 
TCTGCAGCTAAGACTGATGC                  54     20     56.88     50.00     6.00     3.00 
Product Size: 271 
  
-------------------------------------------------------------------------------------- 
  
Oligo 3 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
GAGATGGCTATATTAAGAAATTC             323     23     51.32     30.44     5.00     5.00 
Mutant Reverse Primer 5': 
GAGATGGCTATATTAAGAAATTA               323     23     49.76     26.09     4.00     2.00 
Common Forward Primer 5': 
TGATGCCATTTCTGCTGTAT                  68     20     56.74     40.00     5.00     2.00 
Product Size: 256 
  
-------------------------------------------------------------------------------------- 
  
Oligo 4 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
AGATGGCTATATTAAGAAATTC              322     22     49.40     27.27     5.00     5.00 
Mutant Reverse Primer 5': 
AGATGGCTATATTAAGAAATTA                322     22     47.81     22.73     4.00     2.00 
 	
Common Forward Primer 5': 
TCTGCAGCTAAGACTGATGC                  54     20     56.88     50.00     6.00     3.00 
Product Size: 269 
  
-------------------------------------------------------------------------------------- 
  
Oligo 5 :                                                       Pos.    Len.     Tm       GC%   Self Any   Self 
End 
Wildtype Reverse Primer 5': 
GATGGCTATATTAAGAAATTC               321     21     48.01     28.57     5.00     5.00 
Mutant Reverse Primer 5': 
GATGGCTATATTAAGAAATTA                 321     21     46.36     23.81     4.00     2.00 
Common Forward Primer 5': 
TGATGCCATTTCTGCTGTAT                  68     20     56.74     40.00     5.00     2.00 
Product Size: 254 
  
-------------------------------------------------------------------------------------- 
  
	
F-	Gel	Electrophoresis	Protocol	Pouring	an	agarose	gel			
Assembling	the	gel	box	
• Turn	the	gel	box	so	the	electrodes	are	facing	you	
• Place	the	gel	tray	into	the	box	perpendicular	to	the	box	so	that	the	rubber	gaskets	on	the	side	seal	along	the	edge	of	the	box	(figure	1)	
• There	are	2	notches	for	the	combs-	make	sure	one	set	of	notches	is	on	the	far	side	of	the	gel	box	and	one	set	is	closer	to	you	in	the	middle	(see	figure	2)		
Making	the	gel	
• Measure	100ml	1XPE	buffer	with	a	graduated	cylinder	and	place	in	a	500ml	Erlinmeyer	flask	
• Add	1g	of	agarose	
• Swirl,	then	microwave	(for	the	microwave	in	WLDC201	microwave	for	1	minute	and	15	seconds).	 Figure	4	
Figure	3	
 	
• Remove	from	microwave	with	a		hot	glove,	hold	up	to	the	light	and	swirl	to	make	sure	everything	is	dissolved.		
Pouring	the	gel	
• When	the	gel	has	cooled	slightly,	add	10ul	of	ethidium	bromide	solution	to	100ml	of	gel,	swirl,	and	then	pour	into	the	gel	tray.	FROM	THIS	POINT	FORWARD	YOU	MUST	WEAR	GLOVES	WHEN	TOUCHING	THE	GEL	OR	THE	BUFFER	
• Place	combs	into	the	tray-	the	12	well	comb	should	be	at	the	top	of	the	gel	and	the	20	well	comb	in	the	middle.		Both	should	be	pointing	to	1.5mm	
• Allow	the	gel	to	solidify	
• Immediately	wash	the	flask	out	with	hot	water.		Failure	to	do	so	will	result	in	residual	agarose	gelling	in	the	bottom	of	the	flask	in	which	case	you	will	be	severely	mocked	at	lab	meeting.		
Running	the	gel	
• When	the	gel	has	solidified,	turn	the	gel	perpendicularly	so	that	the	12	well	comb	is	on	the	left.	
• Add	sufficient	1XPE	to	the	gel	box	so	that	the	gel	is	completely	submerged	
• Add	40ul	ethidium	bromide	to	the	gel	box	on	the	right	hand	side.	
• Load	samples	onto	the	gel	and	slide	the	lid	on.	
• Connect	the	electrodes	to	the	power	supply	
• Press	the	set	button	and	check	the	current	(pun	intended)	settings.		Make	sure	the	dials	for	Watts	and	Milliamps	are	at	the	max	and	set	the	voltage	with	the	dial.	
• Press	the	start	button	and	the	light	labeled	DC	should	come	on.		A	few	seconds	later	you	should	hear	a	pop	and	a	few	seconds	after	that	you	should	see	bubbles	in	the	gel	box.	
• If	the	DC	light	fails	to	stay	on,	you	may	have	a	bad	connection	somewhere	so	you	should	go	back	and	recheck	them	all.		Sometimes	you	might	need	to	slide	the	lid	off	and	then	back	on	again.		
Figure	5	
Figure	6	
 	
Disposing	of	the	gel	PUT	ON	GLOVES	Remove	the	gel	from	the	tray	and	place	it	on	a	blue	absorbent	pad	in	the	hood.		When	the	gel	has	dried,	place	it	in	the	yellow	waste	can	in	the	common	room	near	the	ice	machine	(WLDC207	Buffer	should	be	poured	down	the	drain	and	the	gel	tray	and	box	should	be	rinsed	with	DI	water	and	placed	back	in	the	drawer			
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